Survivin与bcl-2基因反义寡核酸联合对人乳腺癌裸鼠皮下移植瘤的治疗作用

目的：本研究旨在探讨survivin与bcl-2基因反义寡脱氧核苷酸联合对人乳腺癌裸鼠皮下移植瘤的治疗作用。方法：在BALB／c裸鼠上建立MCF-7乳腺癌细胞株模型．然后随机分成阴性对照组和5个实验组分别为脂质体survivin正义脱氧寡核苷酸（SODN）组、脂质体bcl-2 SODN组、脂质体survivin反义寡脱氧核苷酸（ASODN）组、脂质体6cl-2 ASODN组、联合反义给药组]。检测裸鼠体重及肿瘤体积变化，计算抑瘤率及肿瘤缩小率。结果：给药后，联合反义给药组的肿瘤体积抑瘤率为78．4％，肿瘤重量抑瘤率为75．3％，肿瘤缩小率为41．6％。在给药后，各组裸鼠体重变化无明显统计学差异（P〉0．05）。结论：survivin与bcl-2基因反义寡核酸联合在体内能明显抑制肿瘤生长。

Therapeutic effects of survivin and bcl-2 gene combined with antisense oligodeoxynucleotide on human breast cancer transplanted subcutaneously in nude mice

AIM: To investigate the effects of survivin and bcl-2 combined with ASODN on the treatment of breast cancer xenograft in nude mice. METHODS: The model of xenografts derived from MCF-7 breast cancer cell was established in BALB/c nude mice, then they were randomly divided into a negative control group and 5 experimental groups intraperitoneal injection of liposome-survivin-SODN, liposome-bcl-2-SODN, liposome-survivin-ASODN, liposome-bcl-2-ASODN, combined ASODN. The tumor growth inhibitory rate and the tumor volume decreased rate were calculated. RESULTS: Survivin and bcl-2 combined with ASODN exhibited potent tumor growth inhibition. The tumor volume inhibitory rate was 78.4 %; the tumor weight inhibitory rate was 75.3 %; the tumor volume decreased rate was 41.6 % for combined group post-experiment of the 6 groups, and there was no significant difference on nude mice weight post-experiment. CONCLUSION: Survivin and bcl-2 combined with ASODN showed potent tumor growth inhibition in vivo.